PPARG and glioblastoma: A recent retrospective clinical review by Grommes showed that diabetic GBM patients treated with PPARγ agonists exhibited an increased median survival of 19 months compared to patients receiving the standard treatment for GBM alone, for whom median survival was 6 months (11).